Showing results (81-90 of 97) with videos related to

Sort By:
Pageof 10
Tumori|April 11, 2022
First-line treatment of metastatic castration-resistant prostate cancer: the real-world Italian cohort of the Prostate Cancer RegistryLuca Galli, Vincenzo Emanuele Chiuri, Giuseppe Di Lorenzo, et al.
The Oncologist|June 2, 2021
Prognostic Role of Circulating Tumor Cells in Metastatic Renal Cell Carcinoma: A Large, Multicenter, Prospective TrialUmberto Basso, Antonella Facchinetti, Elisabetta Rossi, et al.
The Lancet. Oncology|May 17, 2014
Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trialVanesa Gregorc, Silvia Novello, Chiara Lazzari, et al.
European Urology|October 10, 2022
Addition of Niraparib to Best Supportive Care as Maintenance Treatment in Patients with Advanced Urothelial Carcinoma Whose Disease Did Not Progress After First-line Platinum-based Chemotherapy: The Meet-URO12 Randomized Phase 2 TrialFrancesca Vignani, Rosa Tambaro, Ugo De Giorgi, et al.
Advances in Therapy|February 1, 2020
Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter StudyAlessandro Russo, Marco Russano, Tindara Franchina, et al.
BMC Medicine|November 22, 2019
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trialMaria Vittoria Dieci, Giancarlo Bisagni, Alba A Brandes, et al.
Urologic Oncology|April 25, 2015
Clinical outcomes in a contemporary series of "young" patients with castration-resistant prostate cancer who were 60 years and youngerOrazio Caffo, Cinzia Ortega, Giuseppe Di Lorenzo, et al.
Future Oncology (London, England)|January 19, 2016
Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancerAntonello Veccia, Orazio Caffo, Ugo De Giorgi, et al.
Plos One|August 30, 2014
Natural history of malignant bone disease in hepatocellular carcinoma: final results of a multicenter bone metastasis surveyDaniele Santini, Francesco Pantano, Ferdinando Riccardi, et al.
Expert Opinion on Biological Therapy|February 4, 2020
Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving NivolumabFrancesco Pantano, Marco Russano, Alfredo Berruti, et al.
Pageof 10